Powered by OpenAIRE graph
Found an issue? Give us feedback

Impentri

Development of Impentri, an intravenous imatinib formulation for Covid-19 acute respiratory distress syndrome (ARDS).
Funder: European CommissionProject code: 101005142 Call for proposal: H2020-JTI-IMI2-2020-21-single-stage
Funded under: H2020 | IMI2-RIA Overall Budget: 3,985,730 EURFunder Contribution: 3,662,960 EUR
Open Access mandate
Research data: No
visibility
download
views
OpenAIRE UsageCountsViews provided by UsageCounts
downloads
OpenAIRE UsageCountsDownloads provided by UsageCounts
9
25
Description

The accumulation of fluid in the lungs is a significant feature of the pathology in patients with severe Covid-19 infection. This build up of fluid, contributes to difficulty in breathing and in some cases death. This fluid in the lungs results in part from direct damage to cilia and mucus cells and resulting debris and in part due to plasma extravasation triggered by the immune response to infection and associated damage. Imatinib, a generic marketed drug has been shown to reduce plasma extravasation following inflammatory challenge in animal models and this effect is supported by anecdotal observations in the clinic. This project proposes to rapidly implement a multi-center, randomized, open label, double-blind, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of imatinib mesilate in patients with corona-virus associated pneumonitis. 100 patients entering ICU with a diagnosis of corona-virus associated pneumonitis will be randomised, half receiving i.v. imatinob , 200mg bid for 5 days and one half placebo. Adverse events, immunological parameters and imatinib pharmacokineticswill be monitored. Outcome measures Primary: PaO2/FiO2 ratio. Secondary: rate of intubation/need for mechanical ventilation, pulmonary edema on high resolution CT, Oxygenation Index, respiratory mechanics, duration of mechanical ventilation, fluid balance, ICU length of stay, mortality. This project has already received EMA scientific advice for the treatment of acute respirator y distress syndrome and has granted orphan drug status.

Data Management Plans
  • OpenAIRE UsageCounts
    Usage byUsageCounts
    visibility views 9
    download downloads 25
  • 9
    views
    25
    downloads
    Powered byOpenAIRE UsageCounts
Powered by OpenAIRE graph
Found an issue? Give us feedback

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

All Research products
arrow_drop_down
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=corda__h2020::08404afa351c1a0ed1d966699f99f282&type=result"></script>');
-->
</script>
For further information contact us at helpdesk@openaire.eu

No option selected
arrow_drop_down